September 2016

Second of 2 parts: Coverage of the first half of the session appeared in the May issue of Evidence-Based Diabetes Management.1

Second of 2 Parts: See Part 1, in Evidence-Based Diabetes Management, coverage of Patient-Centered Diabetes Care 2016.

For some patients newly diagnosed with type 2 diabetes, skipping metformin monotherapy and going straight to fixed-dose combinations with a DPP-4 inhibitor or an SGLT2 inhibitor makes sense, evidence shows.

Given the growing prevalence of type 2 diabetes (T2D) and its contribution to cardiovascular disease, cardiovascular outcomes trials should aim to be more representative of the average patient with T2D.

Two competing insulin / GLP-1 combinations, one from Sanofi and the other from Novo Nordisk, are under review at FDA.

Officials say the company will file with FDA some time in the third quarter of 2016 to begin the approval process for the novel delivery system that brings a continuous, microscopic dose of exenatide to patients with type 2 diabetes.

Robert A. Gabbay, MD, PhD, FACP, editor-in-chief of Evidence-Based Diabetes Management, discusses the complexities of the current debate over the cost of insulin.

Gaining access to Afrezza can mean battling with an insurer to cover it. Sometimes the first hurdle is getting a doctor to write a prescription, according to those who've been through the process.

Professor R. Keith Campbell, MBA, BPharm, CDE, now retired from Washington State University College of Pharmacy, highlights the clinical advantages of Afrezza based on the evidence as well as his personal perspective.